Physician profile
Robert John March
NPI 1801005012
$17,590.12
in general payments reported to CMS, 2019-2025
82 companies · $4,261 in 2025
The $4,261 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,594 · 2020: $1,350 · 2021: $651 · 2022: $1,677 · 2023: $2,830 · 2024: $3,228 · 2025: $4,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,347 · Education: $972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,347.03 |
| Education | $971.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,238.70 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $1,195.24 | 2019-2025 | |
| Amgen INC. | $973.69 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Merck Sharp & Dohme LLC | $906.30 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $887.46 | 2019-2025 | |
| Gilead Sciences, INC. | $887.30 | 2019-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $832.00 | 2019-2025 | Opdivo, Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $730.94 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Abbvie INC. | $704.90 | 2019-2025 | |
| Astellas Pharma US INC | $686.81 | 2019-2025 | Padcev, Vyloy, Xtandi |
| Exelixis INC. | $426.50 | 2021-2025 | Cabometyx |
| Eisai INC. | $408.63 | 2019-2025 | |
| Lilly USA, LLC | $394.48 | 2019-2025 | Verzenio, Retevmo, Jaypirca |
| Pharmacyclics LLC, An Abbvie Company | $387.84 | 2019-2023 | Epkinly, Imbruvica |
| Incyte Corporation | $356.15 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
Show all 82 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert March listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.